- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change, Trial termination, Trial primary completion date: EASY: Embolectomy in Acute SYlvian Thrombosis in Refractory or Ineligible Patients to ALteplase (clinicaltrials.gov) - Dec 5, 2017 P=N/A, N=2, Terminated, N=41 --> 120 N=250 --> 2 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Aug 2015; After results of other studies published : EASY study became lapsed
- |||||||||| Aggrastat (tirofiban) / Correvio, Medicure, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P2/3 trial: Tirofiban for Patients Treated With Alteplase (clinicaltrials.gov) - Nov 29, 2017 P2/3, N=220, Not yet recruiting,
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: INTRECIS: Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset (clinicaltrials.gov) - Nov 28, 2017 P=N/A, N=3000, Recruiting, N=250 --> 2 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Aug 2015; After results of other studies published : EASY study became lapsed Not yet recruiting --> Recruiting
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Trial primary completion date: EXTEND-IA TNK: Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (clinicaltrials.gov) - Nov 18, 2017 P2, N=202, Active, not recruiting, Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2018 --> Oct 2017
- |||||||||| Pulmozyme (dornase alfa) / Roche, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open: Fibrinolytic Therapy Versus Medical Thoracoscopy (clinicaltrials.gov) - Sep 20, 2017 P4, N=80, Recruiting, Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial initiation date, Trial primary completion date: PHLO: Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial (clinicaltrials.gov) - Sep 20, 2017 P3, N=270, Not yet recruiting, Not yet recruiting --> Recruiting Initiation date: Jul 2017 --> Jul 2018 | Trial primary completion date: Apr 2022 --> Apr 2023
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical: PLATyPuS: Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis (clinicaltrials.gov) - Sep 13, 2017 P2, N=24, Not yet recruiting, Initiation date: Jul 2017 --> Jul 2018 | Trial primary completion date: Apr 2022 --> Apr 2023 Initiation date: Aug 2017 --> Nov 2017
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Surgery: MISTIE III: Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III (clinicaltrials.gov) - Aug 22, 2017 P3, N=500, Active, not recruiting, Initiation date: Aug 2013 --> Jan 2014 | Trial primary completion date: Apr 2014 --> Sep 2016 Recruiting --> Active, not recruiting
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Enrollment change: Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke (clinicaltrials.gov) - Jul 19, 2017 P3, N=501, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=800 --> 501
- |||||||||| Pulmozyme (dornase alfa) / Roche, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P4 trial: Fibrinolytic Therapy Versus Medical Thoracoscopy (clinicaltrials.gov) - Jul 11, 2017 P4, N=80, Not yet recruiting,
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
New P3 trial: THEIA: A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion (clinicaltrials.gov) - Jun 22, 2017 P3, N=70, Not yet recruiting,
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change: EXTEND-IA TNK: Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke (clinicaltrials.gov) - Jun 21, 2017 P2, N=202, Recruiting, Recruiting --> Active, not recruiting | N=800 --> 501 N=64 --> 202
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Trial primary completion date: A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients (clinicaltrials.gov) - Jun 15, 2017 P2a, N=88, Completed, N=64 --> 202 Active, not recruiting --> Completed | Trial primary completion date: Jul 2016 --> Jan 2016
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Treatment Patterns and Short-Term Outcomes in Ischemic Stroke in Pregnancy or Postpartum. (Pubmed Central) - May 27, 2017 Using data from the Get With the Guidelines-Stroke Registry to assemble the largest cohort of pregnant or postpartum ischemic stroke patients who had been treated with reperfusion therapy, we observed that pregnant or postpartum women had similarly favorable short-term outcomes and equal rates of total reperfusion therapy to nonpregnant women, despite lower rates of intravenous tissue plasminogen activator use. Future studies should identify the characteristics of pregnant and postpartum ischemic stroke patients who are most likely to safely benefit from reperfusion therapy.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: Efficacy and Safety of MRI-based Thrombolysis in Wake-up Stroke (clinicaltrials.gov) - May 22, 2017 P3, N=800, Recruiting, Future studies should identify the characteristics of pregnant and postpartum ischemic stroke patients who are most likely to safely benefit from reperfusion therapy. Trial primary completion date: Dec 2016 --> Mar 2018
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: Thrombolysis in Ischemic Spinal Cord Stroke (clinicaltrials.gov) - Apr 13, 2017 P2, N=12, Active, not recruiting, Recruiting --> Suspended | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Oct 2017 --> Oct 2018
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Enrollment change, Trial primary completion date: Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy (clinicaltrials.gov) - Mar 28, 2017 P=N/A, N=50, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=135 --> 50 | Trial primary completion date: May 2014 --> Dec 2017
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion: THE NOR-TEST STUDY: Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke (clinicaltrials.gov) - Mar 28, 2017 P3, N=1050, Completed, Recruiting --> Active, not recruiting | N=135 --> 50 | Trial primary completion date: May 2014 --> Dec 2017 Recruiting --> Completed
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Enrollment change: ACCESS PTS: Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System (clinicaltrials.gov) - Mar 21, 2017 P=N/A, N=113, Active, not recruiting, Recruiting --> Completed Recruiting --> Active, not recruiting | N=200 --> 113
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment closed, Enrollment change: PRISMS: A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke (clinicaltrials.gov) - Feb 23, 2017 P3, N=313, Active, not recruiting, Recruiting --> Active, not recruiting | N=200 --> 113 Terminated --> Active, not recruiting | N=948 --> 313
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial termination, Trial primary completion date: PRISMS: A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke (clinicaltrials.gov) - Feb 20, 2017 P3, N=948, Terminated, Terminated --> Active, not recruiting | N=948 --> 313 Recruiting --> Terminated | Trial primary completion date: May 2018 --> Apr 2017; The study was terminated due to slow enrollment.
- |||||||||| Pulmozyme (dornase alfa) / Roche, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial primary completion date: Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial) (clinicaltrials.gov) - Feb 15, 2017 P3, N=92, Recruiting, Recruiting --> Terminated | Trial primary completion date: May 2018 --> Apr 2017; The study was terminated due to slow enrollment. Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change, Trial termination: TOACT: Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis (clinicaltrials.gov) - Feb 14, 2017 P2/3, N=67, Terminated, Trial primary completion date: Dec 2016 --> Dec 2017 N=164 --> 67 | Recruiting --> Terminated
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment change, Trial primary completion date: Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED) (clinicaltrials.gov) - Dec 13, 2016 P3, N=4700, Recruiting, Not yet recruiting --> Recruiting N=3300 --> 4700 | Trial primary completion date: Dec 2016 --> Dec 2018
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial initiation date, Trial primary completion date: PHLO: Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial (clinicaltrials.gov) - Nov 30, 2016 P3, N=270, Not yet recruiting, N=3300 --> 4700 | Trial primary completion date: Dec 2016 --> Dec 2018 Initiation date: Oct 2016 --> Jul 2017 | Trial primary completion date: Apr 2021 --> Apr 2022
|